Oricell Therapeutics Secures $70 Million in Series C1 Financing to Accelerate Global Innovation and Clinical Development of Cell Therapies

Jan 13, 2026 16:51 CST Updated 16:51

Oricell Therapeutics

Developer of Tumor Immunocyte Products

On January 12, 2026, Oricell Therapeutics, a company focused on the research and development of breakthrough cell therapies, announced that it has completed a C1 round of financing totaling US$70 million. This round of financing was jointly led by Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund. It also attracted investments from several well-known investment institutions, including Qatar Investment Authority (QIA), National Growth Schemes (NGS) of Australia, Yizhuang Guotou, Licheng Investment, and Ruifeng Capital.

As an innovative pioneer in the field of cell therapy drugs, Qrigincell Therapeutics continues to focus on developing CAR-T therapies with global clinical value. Its multiple R&D pipelines have produced convincing Proof-of-Concept (POC) clinical data. The company's core competitiveness stems from its three major self-innovative technology platforms:

Ori®Ab Antibody Screening and Engineering Platform

Ori®Armoring Structural Platform

OnGo(Fast) Process Platform

These platforms jointly build the company's differentiated advantages in the global CAR-T technology field.

Remarkable Progress of Core Products:

Ori-C101 (Targeting GPC3): This autologous CAR-T drug for the treatment of advanced hepatocellular carcinoma (HCC) has completed investigator-initiated research (IIT) and a pivotal Phase I clinical trial, and is about to enter the critical Phase II clinical trial stage. The published clinical data has been presented multiple times at top international academic conferences, demonstrating outstanding efficacy and safety profiles, making it potentially the world’s first approved CAR-T drug for hepatocellular carcinoma.

Innovative Secretory CAR-T (OriC902): Breakthrough efficacy signals have been observed in end-stage solid tumor patients.

Dual-Target in vivo CAR-T: Oricell Therapeutics Holdings Limited's self-developed in vivo dual-target CAR-T therapy has initiated exploratory clinical research, successfully validating the technical feasibility of "Off-the-shelf CAR-T" – a technology capable of directly generating functional CAR-T cells within patients, potentially revolutionizing the accessibility of cell therapies.

This round of financing is of great significance, with the raised USD 70 million to be mainly used for accelerating the company's international strategic layout, comprehensively promoting the clinical development process of core and next-generation products, further consolidating the company’s leading technological strength in the field of cell therapy, and maximizing the value of its diversified industrial pipeline.

About Oricell Therapeutics

Qrigincell Therapeutics is a clinical-stage biotechnology company committed to becoming an innovation-driven global leader in the field of cancer immunotherapy. The company currently focuses on developing innovative cell therapies to address unmet medical needs in the global fields of oncology and immunology. Leveraging proprietary expertise accumulated through its self-developed Ori®Ab antibody screening and engineering platform, Ori®Armoring structural platform, and OnGo(Fast)CMC capabilities, Qrigincell Therapeutics has developed multiple product pipelines for treating solid tumors and hematological malignancies. These have demonstrated promising safety and efficacy in exploratory clinical studies. Relevant clinical research data have been presented at international conferences such as the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, 2025 AACR, 2025 ASCO, 2025 EHA, as well as in the international academic journal *The Lancet Haematology*. Qrigincell Therapeutics is dedicated to advancing the field of cell therapy through innovative technologies, bringing new hope to patients.

Original Link：

https://mp.weixin.qq.com/s/7w9AmzFfWCFJ_cN0YDDLjQ

Bailian Pharmaceutical Immune CellsThe platform has established a full-process service capability ranging from plasmid construction, virus packaging to cell culture. It mainly provides one-stop services for the entire process of plasmid, virus, and cell process development, analytical method development, quality research, and GMP production. Additionally, the company can offer researchers...CAR-NK、UCAR-T、CAR-DNT/γδ T and other novel immunocyte drug registration services. Bialian Pharmaceuticals hasDelivered dozens of IIT and IND projects for immune cell therapies, with successful project experience to help clients solve CMC challenges.

Company Profile:

Biosmelt Pharma was established in 2021 and is located in the Wisdom Plaza of Pujiang Lingang International Technology City in Minhang District, Shanghai. It is a technology service enterprise specializing in CDO/CMO services for ATMP novel drugs.

Bailian Pharmaceutical Shanghai CMC R&D Center covers an area of 3000m², meeting cGMP and BSL-2 laboratory requirements for pathogenic microorganisms. Multiple A-grade production lines have been established that comply with IIT clinical research, IND application, and Phase I clinical trial requirements.Capable of providing full-process services from cell technology R&D, delivery vector development (including tissue targeting), CMC process development, formulation development (including lyophilization), quality research to GMP production, and has successfully delivered dozens of batches of clinical therapeutic drug production to customers.

Main Business:

Core businesses include the development of novel delivery carriers (DD), novel cell technology development (CD), process development (PD), analytical method development (AD), formulation development (FD), quality system development (QD), GMP-level small-scale trial, pilot production, and commercial production services.At the same time, the company also provides services such as registration applications in China, the United States, and Europe, clinical research consulting, and business development for its clients.

Service Product Type:

Universal Cell Drug(Immune cells-CAR-T, CAR-NK, CAR-Macrophage, CAR-Treg, CAR-DNT/γδ T, TIL, TCR-T, DC, Stem cells-MSC, iPSC and derived cells, genetically modified CD34+HSC, etc.);

Gene Delivery Drugs(LV, AAV, Engineered Exosomes, Engineered VLP, Oncolytic Poxvirus, Targeted LNP/mRNA, etc.).

Bailian Pharmaceuticals withInnovative Processes Accelerate Drug AccessibilityOn a mission to fully empower startups, driving the proof-of-concept and commercialization of innovative technologies.

If you have any technical or business needs, please feel free to consult via WeChat.